TITLE

Review: Bisphosphonates are modestly better than placebo for relieving painful bone metastases

AUTHOR(S)
Stockler, Martin
PUB. DATE
July 2005
SOURCE
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p31
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information on a study related to utilization of bisphosphonate agents for the management of pain secondary to bone metastases. Randomized controlled trials (RCTs) that included patients who had bone metastases with or without pain at enrollment, measured pain as an outcome, allowed antineoplastic therapy or rescue pain medications, and compared bisphosphonates with a control intervention. Using a random-effects model, meta-analysis of 5 RCTs showed greater pain relief with bisphosphonates than with placebo.
ACCESSION #
18053696

 

Related Articles

  • The role of bisphosphonates in hormone-refractory prostate cancer. Saad, Fred; Karakiewicz, Pierre; Perrotte, Paul // World Journal of Urology;Jan2005, Vol. 23 Issue 1, p14 

    Men with advanced prostate cancer are at high risk for developing bone metastases, which result in clinically significant skeletal morbidity. Treatments that prevent skeletal complications in these patients could considerably improve their quality of life. Therefore, this paper reviews the role...

  • A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. A F Leger; M Pellan; F Dagousset; A Chevalier; I Keller; J Clerc // British Journal of Radiology;May2005, Vol. 78 Issue 929, p428 

    Thyroid stunning is usually defined as the inhibition or suppression of iodide trapping by remnant thyroid tissue or by functioning metastases following a diagnostic dose of 131I. The risk of stunning increases progressively with larger doses. Because the threshold above which this effect occurs...

  • Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial. D. Loblaw; Jackson Wu; Peter Kirkbride; Katherine Smith; Julie Aslanidis; Padraig Warde // Supportive Care in Cancer;Apr2007, Vol. 15 Issue 4, p451 

    Abstract Background  Short-course radiotherapy is a common treatment for the palliation of painful osseous metastases. Pain flare can be problematic, but its incidence has previously not been well-documented. The objectives of this study were to determine (1) the incidence of pain flare...

  • Role of extracorporeal irradiation in malignant bone tumors. Sharma, D. N.; Rastogi, S.; Bakhshi, S.; Rath, G. K.; Julka, P. K.; Laviraj, M. A.; Khan, S. A.; Kumar, A. // Indian Journal of Cancer;Oct-Dec2013, Vol. 50 Issue 4, p306 

    AIMS AND OBJECTIVES: Extracorporeal irradiation (ECI) is relatively a rare method used in the management of malignant bone tumors (MBT). It consists of en-bloc removal of the tumor bearing bone segment, removal of the tumor from the bone, irradiation, and re-implantation back in the body. We...

  • Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Massard, C.; Zonierek, J.; Gross-Goupil, M.; Fizazi, K.; Szczylik, C.; Escudier, B. // Annals of Oncology;May2010, Vol. 21 Issue 5, p1027 

    Background: This retrospective study evaluated the incidence of brain metastases in a subgroup of patients with metastatic renal cell carcinoma (RCC) who were randomly assigned to receive sorafenib, an oral multikinase inhibitor (400 mg b.i.d.), versus placebo in the phase III Treatment...

  • Advances and Challenges in Diagnosis and Management of Skeletal Metastases. Papagelopoulos, Panayiotis J.; Savvidou, Olga D.; Galanis, Evanthia C.; Mavrogenis, Andreas F.; Jacofsky, David J.; Frassica, Frank J.; Sim, Franklin H. // Orthopedics;Jul2006, Vol. 29 Issue 7, p609 

    Presents a continuing medical education article on the pathophysiology of metastatic bone disease. Effect of bone metastases on destructive skeletal lesion; Treatment goals for patients with metastatic bone disease; Processes involved in metastatic bone disease; Approach used in evaluating...

  • Bone turnover markers and bone scintigraphy in the evaluation of skeletal metastases. Chrapko, Beata E.; Nocuń, Anna; Gotębiewska, Renata; Jankowska, Helena; Zaorska-Rajca, Janina // Nuclear Medicine Review;2005, Vol. 8 Issue 2, p100 

    BACKGROUND: The aim of this study was evaluation of the clinical usefulness of bone scintigraphy and of serum bone turnover marker levels in the assessment of skeletal metastases. MATERIAL AND METHODS: We investigated 60 patients with suspected skeletal metastases. Serum level of bone-formation...

  • Literature meta-analysis of zosteriform cutaneous metastases from melanoma and a clinico-histopathological report from India. Chaudhary, Savita; Bansal, Cherry; Husain, Ayanat // Ecancermedicalscience;2013, Vol. 7, p1 

    Cutaneous metastases in patients with malignant tumours are an important clue to tumour progression or even the first manifestation of malignancy. Among the various topographic patterns of cutaneous metastasis, the zosteriform pattern of metastasis is rare, and very few cases have been...

  • Bisphosphonates and skeletal morbidity in patients with metastatic cancer. Bhandari, Mohit // CMAJ: Canadian Medical Association Journal;11/11/2003, Vol. 169 Issue 10, p1053 

    Summarizes the study "Systematic Review of Role of Bisphosphonates on Skeletal Morbidity in Metastatic Cancer," by J. R. Ross, Y. Saunders, P.M. Edmonds, S. Patel, K.E. Broadley and S. R. Johnston, published in the 2003 issue of the "British Medical Journal." Information on metastatic bone...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics